The ED(50) and ED(95) of remimazolam tosilate to inhibit the gastroscopy reaction in elderly patients of varying ages: an up-and-down sequential allocation trial

瑞米唑仑甲苯磺酸盐抑制不同年龄段老年患者胃镜检查反应的ED(50)和ED(95):一项上下递减序贯分配试验

阅读:1

Abstract

OBJECTIVE: Although remimazolam tosilate (RT) has demonstrated efficacy in elderly gastroscopy, its optimum dose for gastroscopy in elderly patients of varying ages is still unclear. The study aimed to determine the median effective dose (ED(50)) and 95% effective dose (ED(95)) of RT to inhibit the gastroscopy reaction in patients aged 65-74 years and 75-89 years. METHODS: Sixty-one elderly patients were randomized into two groups: Group A (65-74 years, n = 31) and Group B (75-89 years, n = 30). Three minutes after the recruited subjects received 0.1 μg/kg of sufentanil, RT was administered intravenously at an initial dose of 0.15 mg/kg with 0.01 mg/kg step size according to the modified Dixon's up-and-down method (UDM). This continued until nine crossover midpoints "positive-negative" were observed. RESULTS: The ED(50) of RT calculated by the modified UDM for inhibiting the gastroscopy reaction in Group A (0.175 (95% confidence interval, CI, 0.166-0.183) mg/kg) was higher than that in Group B (0.163 (95% CI, 0.156-0.169) mg/kg) (p = 0.03). The ED(95) estimated by probit regression analysis was 0.199 (95% CI, 0.186-0.244) mg/kg in Group A and 0.188 (95% CI, 0.175-0.232) mg/kg in Group B. CONCLUSION: RT is a relatively safe sedative hypnotic that can provide a suitable sedative effect for elderly patients undergoing a gastroscopy. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn, identifier ChiCTR2200062842.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。